Archivum Immunologiae et Therapiae Experimentalis最新文献

筛选
英文 中文
Sanguinarine Inhibits Cell Growth in EBV-Positive Diffuse Large B-Cell Lymphoma.
IF 2.9 4区 医学
Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2025-04-09 eCollection Date: 2025-01-01 DOI: 10.2478/aite-2025-0009
Suli Lu, Dae-Jung Yang
{"title":"Sanguinarine Inhibits Cell Growth in EBV-Positive Diffuse Large B-Cell Lymphoma.","authors":"Suli Lu, Dae-Jung Yang","doi":"10.2478/aite-2025-0009","DOIUrl":"https://doi.org/10.2478/aite-2025-0009","url":null,"abstract":"<p><p>To investigate the effects of Sanguinarine (SAG) on the progression of diffuse large B-cell lymphoma (DLBCL) and to explore its underlying mechanism, this study utilized Epstein-Barr virus (EBV)-positive DLBCL cell lines, FARAGE, and GM12878S. Cell counting kit-8 and bromodeoxyuridine assays were used to assess the effects of SAG on the cell proliferation. Flow cytometry and immunoblotting were employed to analyze cell cycle arrest and apoptosis. Additionally, the molecular mechanism was explored through further immunoblotting analysis of the mechanism. SAG suppressed the growth of EBV-positive DLBCL cells. Furthermore, SAG induced cell cycle arrest and promoted apoptosis in these cells. Mechanistically, SAG suppressed the Wnt/β-catenin pathway, thereby suppressing DLBCL progression <i>in vitro</i>. SAG effectively inhibits cell growth and induces apoptosis in EBV-positive DLBCL via Wnt/β-catenin pathway, offering potential therapeutic insights for this lymphoma subtype.</p>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"73 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thrombotic Markers in Plasma as Predictors of Response in Rheumatoid Arthritis Patients Treated with Baricitinib - Pilot Observation.
IF 2.9 4区 医学
Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2025-04-09 eCollection Date: 2025-01-01 DOI: 10.2478/aite-2025-0010
Anna Felis-Giemza, Kornelia Chmurzynska, Jakub Wronski, Paulina Klimek, Anna Kornatka, Wlodzimierz Maslinski, Marzena Ciechomska, Magdalena Massalska
{"title":"Thrombotic Markers in Plasma as Predictors of Response in Rheumatoid Arthritis Patients Treated with Baricitinib - Pilot Observation.","authors":"Anna Felis-Giemza, Kornelia Chmurzynska, Jakub Wronski, Paulina Klimek, Anna Kornatka, Wlodzimierz Maslinski, Marzena Ciechomska, Magdalena Massalska","doi":"10.2478/aite-2025-0010","DOIUrl":"https://doi.org/10.2478/aite-2025-0010","url":null,"abstract":"<p><p>Both disease and treatment carry the risk of thrombotic events in patients with rheumatoid arthritis (RA). This pilot study aimed to assess changes in thrombotic markers in plasma and their potential role as predictors of response during early baricitinib treatment. The concentrations of antithrombin III (ATIII) activity, D-dimer (DD), fibrinogen, and homocysteine (HCY) were evaluated in RA subjects before and 3 months after the treatment. At baseline, the RA group had higher DD (1472.3 ± 349.2) and fibrinogen (410.4 ± 29.5) compared with healthy controls (HC; 450.3 ± 54.5; <i>p</i> = 0.0002 and 334.9 ± 19.2; <i>p</i> = 0.04, respectively). with no differences in ATIII and HCY. After 3 months, we observed a significant increase in HCY (10.7 ± 0.6 vs. 9.1 ± 0.5; <i>p</i> = 0.018) and ATIII (119.7 ± 2.7 <i>vs</i>. 110.4 ± 3.2; <i>p</i> = 0.004), the latter correlated negatively with disease activity score 28 (DAS28; <i>r</i> = -0686, <i>p</i> < 0.002). After 3 months of baricitinib therapy, the patients were divided into moderate responders (MR) and good responders (GR) groups according to EULAR criteria. At baseline, MR had higher DD (1639.2 ± 550.5 <i>vs</i>. 450.3 ± 54.5; <i>p</i> < 0.0001) and lower ATIII (105.3 ± 3.6 <i>vs</i>. 115.1 ± 2.7; <i>p</i> = 0.043) compared with HC. Thrombotic parameters in the first 3 months of baricitinib treatment were mostly in line with current findings concerning the RA population. Increased levels of DD together with low ATIII concentrations seem to predispose to a moderate response to baricitinib treatment.</p>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"73 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protective Effect of the Human Epineural Patch Application after Sciatic Nerve Crush Injury Followed by Nerve Transection and End-to-End Repair.
IF 2.9 4区 医学
Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2025-03-26 eCollection Date: 2025-01-01 DOI: 10.2478/aite-2025-0008
Maria Siemionow, Weronika Radecka, Katarzyna Kozlowska, Lucile Chambily, Sonia Brodowska, Dominika Kuc, Gabrielle Filipek, Katarzyna Budzynska
{"title":"Protective Effect of the Human Epineural Patch Application after Sciatic Nerve Crush Injury Followed by Nerve Transection and End-to-End Repair.","authors":"Maria Siemionow, Weronika Radecka, Katarzyna Kozlowska, Lucile Chambily, Sonia Brodowska, Dominika Kuc, Gabrielle Filipek, Katarzyna Budzynska","doi":"10.2478/aite-2025-0008","DOIUrl":"https://doi.org/10.2478/aite-2025-0008","url":null,"abstract":"<p><p>Nerve regeneration under unfavorable wound conditions remains challenging. We introduce the human epineural patch (hEP) as a novel nerve protector for post-trauma applications, comparing its regenerative efficacy with that of the human amniotic membrane (hAM). Following crush injury, transection, and end-to-end repair (CTR), 36 athymic nude rats were randomly assigned to six experimental groups (<i>n</i> = 6 each): control (no-protection), hEP, or hAM application post-repair. Assessments at 6 weeks and 12 weeks included functional evaluation (Toe-Spread and Pinprick tests), gastrocnemius muscle index (GMI), histomorphometric analysis (myelin thickness, axonal density, fiber diameter, percentage of myelinated fibers), and immunofluorescence staining for neurogenic, angiogenic, and immunogenic markers. The hEP group exhibited superior motor (3.167 ± 0.167) and sensory (3.500 ± 0.212) recovery and GMI values (0.955 ± 0.014), compared with the No protection group (<i>p</i> < 0.05). Myelin thickness (3.480 ± 0.019 µm, <i>p</i> < 0.0001), fiber diameter (10.788 ± 0.197 µm, <i>p</i> < 0.05), and myelinated fiber percentage (89.841% ± 0.453%, <i>p</i> < 0.01) were significantly higher in the hEP group. At 12 weeks, hEP application significantly increased the expression of Laminin B (2.083 ± 0.083), nerve growth factor (NGF) (1.750 ± 0.250), and vascular endothelial growth factor (VEGF) (2.667 ± 0.333), corresponding with improved function. The application of hEP at the sciatic nerve repair site after CTR injury significantly enhanced nerve regeneration compared with hAM. This study introduces hEP as a promising alternative nerve protector for traumatic nerve injuries.</p>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"73 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143727581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunomodulatory Effect of the Bacillus Calmette-Guérin (BCG) Vaccine on the In Vitro Interferon Response Induced by Respiratory Syncytial Virus (RSV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigens.
IF 2.9 4区 医学
Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2025-03-18 eCollection Date: 2025-01-01 DOI: 10.2478/aite-2025-0007
Magdalena Jurczak, Joanna Kaczmarek, Magdalena Kowalewska-Pietrzak, Magdalena Druszczynska
{"title":"Immunomodulatory Effect of the Bacillus Calmette-Guérin (BCG) Vaccine on the <i>In Vitro</i> Interferon Response Induced by Respiratory Syncytial Virus (RSV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigens.","authors":"Magdalena Jurczak, Joanna Kaczmarek, Magdalena Kowalewska-Pietrzak, Magdalena Druszczynska","doi":"10.2478/aite-2025-0007","DOIUrl":"10.2478/aite-2025-0007","url":null,"abstract":"<p><p>Studies on the bacillus Calmette-Guérin (BCG) vaccine, traditionally used against tuberculosis, indicate its potential benefit in protecting against infections. The vaccine's ability to broadly activate the immune system suggests its potential to bolster non-specific immunity, which could be crucial for combating respiratory pathogens. This study aimed to evaluate the messenger RNA (mRNA) expression of interferon (IFN)-α, IFN-β, and IFN-γ as well as the secretion of these cytokines in whole blood co-stimulated cultures with BCG and antigens of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or respiratory syncytial virus (RSV) from BCG-vaccinated Polish children who have been infected or uninfected with RSV and/or SARS-CoV-2. Significant differences were observed in the secretion and mRNA expression of IFN-α and IFN-γ in response to RSV antigens in all groups of children studied. When cultures were conducted in the presence of SARS-CoV-2 antigens, live BCG did not induce increased IFN-α secretion compared with cultures stimulated with these antigens alone. However, enhanced secretion was observed for IFN-γ, and no such relationship was observed for mRNA expression. Furthermore, discrepancies between IFN-β secretion and mRNA expression were observed, suggesting that IFN protein secretion can also be controlled at the translational or posttranslational level. The data from our studies indicate that BCG vaccination may modulate the IFN response to viral challenges with SARS-CoV-2 and RSV, suggesting a potential immunoregulatory role.</p>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"73 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Growing Challenges of Lung Infections with Non-tuberculous Mycobacteria in Immunocompromised Patients: Epidemiology and Treatment.
IF 2.9 4区 医学
Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2025-03-14 eCollection Date: 2025-01-01 DOI: 10.2478/aite-2025-0005
Weronika Burzyńska, Marek Fol, Magdalena Druszczynska
{"title":"Growing Challenges of Lung Infections with Non-tuberculous Mycobacteria in Immunocompromised Patients: Epidemiology and Treatment.","authors":"Weronika Burzyńska, Marek Fol, Magdalena Druszczynska","doi":"10.2478/aite-2025-0005","DOIUrl":"https://doi.org/10.2478/aite-2025-0005","url":null,"abstract":"<p><p>Non-tuberculous mycobacteria (NTM) are increasingly recognized as opportunistic pathogens in humans and animals, particularly affecting those with compromised immune systems. These bacteria encompass a diverse group of mycobacterial species that are responsible for a range of infections, with pulmonary and skin-related conditions being the most common. The rise in NTM infections in recent years is a growing concern for healthcare, highlighting the urgent need to improve our understanding of NTM epidemiology and treatment strategies. This article reviews the NTM species associated with lung infections in immunocompromised patients and underscores the critical importance of advancing diagnostic and therapeutic approaches. The review is based on a thorough analysis of scientific literature from databases such as PubMed, Scopus, and ScienceDirect, covering studies up to June 2024. Through this comprehensive analysis, the article aims to provide detailed insights into the complexities of NTM diseases and spur further research and innovation in combating these challenging infections.</p>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"73 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isorhynchophylline Inhibits NLRP3 Inflammasome and Improves Gestational Diabetes.
IF 2.9 4区 医学
Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2025-03-14 eCollection Date: 2025-01-01 DOI: 10.2478/aite-2025-0006
Li Pu, Li Chen, Kun Yu, Yueming Zhang, Caifeng Wang, Feizhou Jiang, Jia Shi, Jingjing Meng
{"title":"Isorhynchophylline Inhibits NLRP3 Inflammasome and Improves Gestational Diabetes.","authors":"Li Pu, Li Chen, Kun Yu, Yueming Zhang, Caifeng Wang, Feizhou Jiang, Jia Shi, Jingjing Meng","doi":"10.2478/aite-2025-0006","DOIUrl":"https://doi.org/10.2478/aite-2025-0006","url":null,"abstract":"<p><p>This study aims to investigate the effects and underlying mechanisms of isorhynchophylline (IRN) on gestational diabetes mellitus (GDM). The db/+ mice were randomly divided into four groups: GDM, GDM + IRN (20 mg/kg), and GDM + IRN (40 mg/kg). Blood glucose and insulin tolerance were assessed using intraperitoneal glucose tolerance tests (IPGTTs) and intraperitoneal insulin tolerance tests (IPITTs) on gestational day 10. On gestational day 20, placental inflammation (tumor necrosis factor [TNF]-α, interleukin [IL]-6, IL-1β), oxidative stress markers (malondialdehyde [MDA], SOD, glutathione peroxidase [GPx], and glutathione [GSH]), and nuclear factor-κB/NOD-like receptor protein 3 [NLRP3] inflammasome activity were measured using enzyme-linked immunosorbent assay (ELISA), immunoblotting, and biochemical assays. IRN significantly improved blood glucose levels and insulin tolerance in GDM mice. IRN treatment reduced placental inflammation. In addition, oxidative stress in the placenta was alleviated in the IRN-treated groups, leading to improved placental function and healthier fetal development. The birth weight of offspring was higher in the IRN-treated groups compared with untreated GDM mice. Furthermore, IRN inhibited the activation of the NLRP3 pathway. IRN significantly improves metabolic and inflammatory parameters in GDM through the NF-κB/NLRP3 pathway, highlighting its potential therapeutic benefits for managing GDM and improving maternal and fetal outcomes.</p>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"73 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antinuclear Antibodies in Non-Rheumatic Diseases. 非风湿性疾病中的抗核抗体。
IF 2.9 4区 医学
Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2025-01-19 eCollection Date: 2025-01-01 DOI: 10.2478/aite-2025-0004
Nikita Niranjan Kumar, Samir Ahmad Dit Al Hakim, Bogna Grygiel-Górniak
{"title":"Antinuclear Antibodies in Non-Rheumatic Diseases.","authors":"Nikita Niranjan Kumar, Samir Ahmad Dit Al Hakim, Bogna Grygiel-Górniak","doi":"10.2478/aite-2025-0004","DOIUrl":"https://doi.org/10.2478/aite-2025-0004","url":null,"abstract":"<p><p>Antinuclear antibodies (ANAs) are critical immunological markers commonly associated with various connective tissue diseases (CTDs). However, these autoantibodies are also detectable in healthy individuals, patients with non-rheumatic autoimmune diseases, those with viral infections, and subjects using specific medications (such as procainamide, hydralazine, and minocycline) that can lead to drug-induced ANA elevation. The standard method for ANA detection is indirect immunofluorescence, a process that requires precision and thoroughness as it assesses both titer and fluorescence patterns. Additionally, immunoblotting and enzyme-linked immunosorbent assay (ELISA) are recommended to identify specific ANAs precisely, highlighting the importance of precision in ANA detection. This review explores the advantages and limitations of current ANA detection methods. It also describes the clinical implications of ANA presence in non-rheumatic diseases, including autoimmune disorders, infectious conditions, non-autoimmune and non-infectious diseases, and autoimmune cutaneous diseases. The presence of elevated ANA titers in these contexts can complicate clinical decision-making, as the diagnostic value of ANA testing alone is limited in non-rheumatic conditions. However, despite these limitations, ANA remains a key component in diagnosing and prognosis systemic CTDs, as it can indicate disease activity, severity, and response to treatment, which is of utmost importance in rheumatology and internal medicine. This paper provides a comprehensive review of the role of ANA in non-rheumatic diseases. It focuses on ANA diagnostic and prognostic significance and offers valuable insights for clinical practice.</p>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"73 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CRISPR/Cas Systems as Diagnostic and Potential Therapeutic Tools for Enterohemorrhagic Escherichia coli. CRISPR/Cas系统作为肠出血性大肠杆菌的诊断和潜在治疗工具
IF 2.9 4区 医学
Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2025-01-07 eCollection Date: 2025-01-01 DOI: 10.2478/aite-2025-0003
Agnieszka Bogut, Anna Kołodziejek, Scott A Minnich, Carolyn J Hovde
{"title":"CRISPR/Cas Systems as Diagnostic and Potential Therapeutic Tools for Enterohemorrhagic <i>Escherichia coli</i>.","authors":"Agnieszka Bogut, Anna Kołodziejek, Scott A Minnich, Carolyn J Hovde","doi":"10.2478/aite-2025-0003","DOIUrl":"10.2478/aite-2025-0003","url":null,"abstract":"<p><p>Following its discovery as an adaptive immune system in prokaryotes, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) system has been developed into a multifaceted genome editing tool. This review compiles findings aimed at implementation of this technology for selective elimination or attenuation of enterohemorrhagic <i>Escherichia coli</i> (EHEC). EHEC are important zoonotic foodborne pathogens that cause hemorrhagic colitis and can progress to the life-threatening hemolytic uremic syndrome (HUS). Advancements in the application of CRISPR methodology include laboratory detection and identification of EHEC, genotyping, screening for pathogenic potential, and engineering probiotics to reduce microbial shedding by cattle, the primary source of human infection. Genetically engineered phages or conjugative plasmids have been designed to target and inactivate genes whose products are critical for EHEC virulence.</p>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"73 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142943408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantification of Citrullinated Histone H3 as a Marker for Neutrophil Extracellular Traps Correlated to Clinical Characteristics of Patients with Systemic Lupus Erythematosus. 瓜氨酸化组蛋白H3作为中性粒细胞胞外陷阱标志物与系统性红斑狼疮患者临床特征相关的定量分析。
IF 2.9 4区 医学
Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2025-01-03 eCollection Date: 2025-01-01 DOI: 10.2478/aite-2025-0002
Maciej Dubaj, Iwona Homa-Mlak, Aleksandra Majdan, Radosław Mlak, Maria Majdan, Teresa Małecka-Massalska
{"title":"Quantification of Citrullinated Histone H3 as a Marker for Neutrophil Extracellular Traps Correlated to Clinical Characteristics of Patients with Systemic Lupus Erythematosus.","authors":"Maciej Dubaj, Iwona Homa-Mlak, Aleksandra Majdan, Radosław Mlak, Maria Majdan, Teresa Małecka-Massalska","doi":"10.2478/aite-2025-0002","DOIUrl":"https://doi.org/10.2478/aite-2025-0002","url":null,"abstract":"<p><p>Systemic lupus erythematosus (SLE) is an autoimmune disease whose pathogenesis is not fully understood to date. One of the suggested mechanisms for its development is NETosis, which involves the release of a specific network consisting of chromatin, proteins, and enzymes from neutrophils, stimulating the immune system. One of its markers is citrullinated histone H3 (H3Cit). This study aimed to evaluate the correlation of H3Cit levels with the clinical characteristics of 80 SLE patients. Levels of H3Cit in the subjects' serum were quantified spectrophotometrically. Statistical analysis was performed using MedCalc 15.8 and Statistica 13.3. Significantly higher H3Cit levels were found in patients with arthralgia (medians [interquartile range] [IQR]: 1.67 [1.67-1.69] <i>vs</i>. 1.67 [1.62-1.68], <i>p</i> = 0.0150, respectively) and reduced complement component C4 levels compared to patients without these conditions (medians [IQR]: 1.68 [1.67-1.70] <i>vs</i>. 1.68 [1.67-1.69], <i>p</i> = 0.0297, respectively). A significant weak negative correlation was observed between H3Cit levels and leukocytosis (rho = -0.2602, <i>p</i> = 0.0309) and reduced complement component C3 levels (rho = -0.2442, <i>p</i> = 0.0447) and a weak positive correlation with anti-double stranded DNA (anti-dsDNA) antibody levels (rho = 0.3794, <i>p</i> = 0.0036). Moreover, the clinical utility of the H3Cit assay in differentiating patients with arthralgia (area under the curve [AUC] = 0.709, <i>p</i> = 0.0115), seizures (AUC = 0.813, <i>p</i> = 0.0005), hepatomegaly (AUC = 0.746, <i>p</i> = 0.0111), and reduced levels of complement component C4 (AUC = 0.662, <i>p</i> = 0.0224) and without the above conditions was noted.</p>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"73 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Asymptomatic Hyperuricemia: A Nephro-Rheumatological Perspective. 无症状高尿酸血症:肾风湿病学的观点。
IF 2.9 4区 医学
Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2024-11-29 eCollection Date: 2024-01-01 DOI: 10.2478/aite-2024-0024
Barbara Moszczuk, Katarzyna Życińska, Krzysztof Mucha
{"title":"Asymptomatic Hyperuricemia: A Nephro-Rheumatological Perspective.","authors":"Barbara Moszczuk, Katarzyna Życińska, Krzysztof Mucha","doi":"10.2478/aite-2024-0024","DOIUrl":"10.2478/aite-2024-0024","url":null,"abstract":"<p><p>Hyperuricemia (HU) is a common disorder associated with gout, kidney injury, and high cardiovascular risk. However, whether high serum uric acid (sUA) is a causative factor or just comorbidity remains unclear. When asked if asymptomatic hyperuricemic patients need treatment, even artificial intelligence in the form of the GPT chat provides an ambivalent answer and refers us to a healthcare provider. We believe that such discrepancies stem from an incomplete understanding of the role that uric acid (UA) plays inside and outside the cell. With the rapid development of genomics, proteomics, immunology, and novel biomarkers, we are armed with new data to help us better understand the weight of inborn and environmental factors on an individual's UA concentrations. This review sums up the latest progress that has been made in the field of asymptomatic HU, compares the results presented by various research teams, and indicates new directions that emerge for future studies.</p>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"72 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142754456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信